Literature DB >> 9757811

[Response of osteoblast cultures to titanium, steel and hydroxyapatite implants].

O A Trentz1, A Platz, N Helmy, O Trentz.   

Abstract

The biocompatibility of bone implants and substitutes is usually tested on cell-lines only, despite a different and more relevant behaviour on primary osteoblasts as final targets can be expected. "Osteoblast-like" cell line (MC3T3-E1) and fresh human osteoblasts (HOB), cultured from cancellous bone grafts from the iliac crest were used for the study. Three different clinically used biomaterials were compared regarding biocompatibility: titanium, steel and hydroxyapatite (Bio-Oss). "Osteoblast-like" cell line and fresh human osteoblasts (5x104) were seeded on the three bone implants. Cell proliferation and osteocalcin synthesis were determined 1, 3, 7, and 10 days after the cells were plated on the biomaterials. All experiments were performed in five times (pro culture double measurements). HOB proliferation on hydroxyapatite was decreasing after 3 days, whereas cells from "Osteoblast-like" cell line showed comparable proliferation to the control group. The most interesting observation was the significant decrease of the osteocalcin levels (in conditioned medium) of "osteoblast like" cells and HOB on HA (Bio-Oss). We conclude that HA disturbs the proliferation and osteocalcin synthesis of HOB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9757811

Source DB:  PubMed          Journal:  Swiss Surg        ISSN: 1023-9332


  2 in total

1.  Titanium--hydroxyapatite porous structures for endosseous applications.

Authors:  C Popa; V Simon; I Vida-Simiti; G Batin; V Candea; S Simon
Journal:  J Mater Sci Mater Med       Date:  2005-12       Impact factor: 3.896

2.  Surface- and nonsurface-dependent in vitro effects of bone substitutes on cell viability.

Authors:  M Herten; D Rothamel; F Schwarz; K Friesen; G Koegler; J Becker
Journal:  Clin Oral Investig       Date:  2008-08-08       Impact factor: 3.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.